Law Firms Seek Regencell Investors to Lead Securities Fraud Class Action

Overview

• A securities class action was filed against Regencell Bioscience Holdings, and Rosen Law Firm and Glancy Prongay Wolke & Rotter are inviting investors to seek lead‑plaintiff status by June 23, 2026.
• The notices apply to people who bought Regencell shares between October 28, 2024 and October 31, 2025.
• The lawsuit alleges the company misled investors about the risk that its stock could be manipulated, which the complaint says led to sharp price swings.
• It further claims those swings exposed investors to losses and increased the chance of regulatory or government scrutiny of the company.
• No class has been certified, so investors are not represented unless they hire counsel, and the press releases are attorney advertising that offer contingency‑fee representation.